

Reduction of common stock



March 27, 2015

Reduction of common stock

Pursuant to company announcement no. 11, 2015, a reduction of the company's B common stock by DKK 13,400,000 via cancellation of 6,700,000 treasury B stocks was adopted at the Annual Shareholders' Meeting of Novozymes A/S on February 25, 2015.

Today, Novozymes has registered the final implementation of the reduction of its common stock with the Danish Business Authority. Consequently, the reduction of Novozymes' B common stock from DKK 531,912,800 to DKK 518,512,800 is complete.

After the reduction, the common stock is DKK 626,000,000, divided into 313 million shares of DKK 2.

Share capital overview	Share capital, DKK	Number of shares, DKK 2
A-shares	107.487.200	53.743.600
B-shares	518.512.800	259.256.400
Samlet	626.000.000	313.000.000

As communicated in company announcement no. 17, 2014, Novo A/S intends to reduce its relative holding of Novozymes' B common stock so that it will continue to hold around 25.5% of the total common stock following Novozymes' cancellation of 6,700,000 treasury B shares.

On March 27, 2015, following the reduction of its common stock, Novozymes' holding of treasury shares was 5.22 million B shares, equivalent to 1.67% of the reduced total share capital of DKK 626,000,000.

Contact information

Investor Relations:

Thomas Bomhoff (DK)	+45 3077 1226	tsbm@novozymes.com
Klaus Sindahl (DK)	+45 5363 0134	ksdh@novozymes.com
Martin Riise (USA)	+1 919 649 2565	mrsn@novozymes.com

Novozymes is the world leader in bioinnovation. Together with customers across a broad array of industries we create tomorrow's industrial biosolutions, improving our customers' business and the use of our planet's resources. Read more at www.novozymes.com.